VERTEX PHARMACEUTICALS INC / MA Operating Lease Cost
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Operating Lease Cost of $194.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-13
- VERTEX PHARMACEUTICALS INC / MA operating lease, cost for the quarter ending 2024-12-31 was -$1.20B.
- VERTEX PHARMACEUTICALS INC / MA operating lease, cost for the quarter ending 2019-12-31 was $3.94M.
- VERTEX PHARMACEUTICALS INC / MA operating lease, cost for the quarter ending 2019-09-30 was $2.80M.
- VERTEX PHARMACEUTICALS INC / MA operating lease, cost for the quarter ending 2019-06-30 was $2.63M.
- VERTEX PHARMACEUTICALS INC / MA operating lease, cost for fiscal 2025 was $194.70M, a 87.39% increase from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA operating lease, cost for fiscal 2024 was $103.90M, a 117.36% increase from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA operating lease, cost for fiscal 2023 was $47.80M, a 35.41% increase from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA operating lease, cost for fiscal 2022 was $35.30M, a 4.13% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $194.70M 10-K · filed 2026-02-13 | ||||
| 2024-12-31 | -$1.20B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $103.90M 10-K · filed 2026-02-13 | |||
| 2024-09-30 | $1.30B 10-Q · filed 2024-11-05 | ||||
| 2023-12-31 | $47.80M 10-K · filed 2026-02-13 | ||||
| 2022-12-31 | $35.30M 10-K · filed 2025-02-13 | ||||
| 2021-12-31 | $33.90M 10-K · filed 2024-02-15 | ||||
| 2020-12-31 | $23.10M 10-K · filed 2023-02-10 | $23.13M 10-K · filed 2021-02-11 | |||
| 2019-12-31 | $3.94M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $6.73M derived: sum of 2 quarters · filed 2022-02-09 | $9.36M derived: sum of 3 quarters · filed 2022-02-09 | $12.00M 10-K · filed 2022-02-09 | $11.97M 10-K · filed 2020-02-13 |
| 2019-09-30 | $2.80M 10-Q · filed 2019-10-31 | $5.42M derived: sum of 2 quarters · filed 2019-10-31 | $8.06M 10-Q · filed 2019-10-31 | ||
| 2019-06-30 | $2.63M 10-Q · filed 2019-08-01 | $5.27M 10-Q · filed 2019-08-01 | |||
| 2019-03-31 | $2.64M 10-Q · filed 2019-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |